Status:
COMPLETED
COVID-19 and ICU-acquired MDR Bacteria
Lead Sponsor:
University Hospital, Lille
Conditions:
Sars-CoV2
Critical Illness
Eligibility:
All Genders
18+ years
Brief Summary
This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.
Detailed Description
Multicenter observational before-after study, aiming to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired colonization and infection related to MDR bacteria.
Eligibility Criteria
Inclusion
- Expected ICU stay \> 48 hours
- Rectal and nasal BMR screening performed \< 48 hours after admission to ICU
Exclusion
- Patients aged \< 18 years Refusal to take part in the study ICU-stay \< 48 hours At least a second rectal and nasal BMR screening was not performed prior to ICU discharge (a posteriori exclusion criterion).
Key Trial Info
Start Date :
May 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 26 2021
Estimated Enrollment :
368 Patients enrolled
Trial Details
Trial ID
NCT04378842
Start Date
May 18 2020
End Date
July 26 2021
Last Update
October 5 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Amiens Picardie
Amiens, France
2
Ch Bethune
Béthune, France
3
Grand Hopital de L'Est Francilien
Jossigny, France
4
CH LENS
Lens, France